Evaluation and management of platelet transfusion refractoriness.

Content Provider	Europe PMC
Author	Youk, Hee-Jeong Hwang, Sang-Hyun Oh, Heung-Bum Ko, Dae-Hyun
Copyright Year	2022
Abstract	Platelet transfusion refractoriness (PTR), in which platelet counts do not increase after transfusion, occurs in many patients receiving platelet transfusions. PTR is a clinical condition that can harm patients. The causes of PTR can be divided into two types: immune and non-immune. Most cases of PTR are non-immune. Among immune causes, the most common is human leukocyte antigen (HLA) class I molecules. PTR caused by anti-HLA antibodies is usually managed by transfusing HLA-matched platelets. Therefore, it is important, especially for hemato-oncologists who frequently perform transfusion, to accurately diagnose whether the cause of platelet transfusion failure is alloimmune or non-immunological when determining the treatment direction for the patient. In this review, we discuss the definitions, causes, countermeasures, and prevention methods of PTR.
Related Links	https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC9057673&blobtype=pdf
ISSN	2287979X
Volume Number	57
DOI	10.5045/br.2022.2021229
PubMed Central reference number	PMC9057673
Issue Number	Suppl 1
Issue Number	s1
PubMed reference number	35483919
Journal	Blood research [Blood Res]
e-ISSN	22880011
Language	English
Publisher	Korean Society of Hematology
Publisher Date	2022-04-01
Access Restriction	Open
Rights License	This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. © 2022 Korean Society of Hematology
Subject Keyword	Platelet transfusion refractoriness Platelet transfusion Human leukocyte antigen HLA-matched Platelet count
Content Type	Text
Resource Type	Article
Subject	Hematology